Citations

Clear

6273 citation(s) found for "To, Andrew".

IC‐P‐098: The role of APOE‐ɛ4 genotype in early mild cognitive impairment (EMCI): Preliminary results from ADNI‐2
Kim, Sungeun , Ngo, Kwangsik, Petersen, Ronald C. , Aisen, Paul , Jagust, William J. , Weiner, Michael W. , Risacher, Shannon L. , Shen, Li , Foroud, Tatiana , Jack, Clifford R. , Koeppe, Robert A. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2012.05.131 Get It

O4‐01‐01: Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of Aß, tau and P‐tau versus 83 proteomic analytes
Yan, Jingwen , Shaw, Leslie M. , Trojanowski, John Q. , Aisen, Paul, Petersen, Ronald C. , Weiner, Michael W. , Li, Taiyong , Kim, Sungeun , Swaminathan, Shanker , Risacher, Shannon L. , Saykin, Andrew J. , Shen, Li

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2012.05.1634 Get It

P3‐212: Hippocampal subfield atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort: Relationships to diagnosis and memory impairment
Boddu, Mohan, West, John D. , Wan, Jing , Weiner, Michael W. , Initiative, The Alzheimer's Disease Neuroimaging, Ramanan, Vijay K. , Shen, Li , Risacher, Shannon L. , Kim, Sungeun , Wang, Yang , Crane, Paul K. , Jack, Clifford R. , Saykin, Andrew J. , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2012.05.1434 Get It

Emergencies in Neuro-Ophthalmology
Brazis, Paul W., Mughal, Mansoor , Policeni, Fabiana , Lee, Andrew G.

Mayo Clinic

No container title available | July 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1142/7615 Get It

SDF-1α Degrades whereas Glycoprotein 120 Upregulates Bcl-2 Interacting Mediator of Death Extralong Isoform: Implications for the Development of T Cell Memory
Trushin, Sergey A., Carena, Alberto , Bren, Gary D., Rizza, Stacey A. , Dong, Xiangyang , Abraham, Roshini S. , Badley, Andrew D. , Badley, Andrew D

Mayo Clinic

The Journal of Immunology | July 17, 2012 | Volume: 189 | Issue: 4 | Pages: 1835-1842

10.4049/jimmunol.1100275 | PMID 22802411 Get It

Abstract After a primary immune response, T cell memory occurs when a subset of Ag-specific T cells resists peripheral selection by acquiring resistance to TCR-induced death. Recent data have implicated Bcl-2 interacting mediator of death (Bim) as an essential mediator of the contraction phase of T cell immunity. In this article, we describe that stromal-derived factor-1α (SDF-1α) ligation of CXCR4 on activated T cells promotes two parallel processes that favor survival, phospho-inactivation of Foxo3A, as well as Bim extralong isoform (BimEL) degradation, both in an Akt- and Erk-dependent manner. Activated primary CD4 T cells treated with SDF-1α therefore become resistant to the proapoptotic effects of TCR ligation or IL-2 deprivation and accumulate cells of a memory phenotype. Unlike SDF-1α, gp120 ligation of CXCR4 has the opposite effect because it causes p38-dependent BimEL upregulation. However, when activated CD4 T cells are treated with both gp120 and SDF-1α, the SDF-1α–driven effects of BimEL degradation and acquired resistance to TCR-induced death predominate. These results provide a novel causal link between SDF-1α–induced chemotaxis, degradation of BimEL, and the development of CD4 T cell memory.
Large-scale replication and heterogeneity in Parkinson disease genetic loci
Sharma, Manu , Aasly, Jan , Annesi, Grazia , Brice, Alexis , Broeckhoven, Christine Van , Bozi, Maria , Crosiers, David , Clarke, Carl E , Facheris, Maurizio , Farrer, Matthew J. , Garraux, Gaëtan , Gispert, Suzana, Auburger, Georg , Vilariño‐Güell, Carles , Hicks, Andrew A. , Hattori, Nobutaka , Jeon, Beom S., Lesage, Suzanne , Lill, Christina M. , Lin, Juei-Jueng, Lynch, Timothy , Lichtner, Peter , Lang, Anthony E. , Jasińska‐Myga, Barbara, Mellick, George D. , Morrison, Karen , Opala, Grzegorz, Pramstaller, Peter P. , Pichler, Irene , Park, Sung Sup , Quattrone, Aldo , Ross, Owen A. , Stockton, Joanne , Satake, Wataru , Silburn, Peter A., Theuns, Jessie , Tan, Eng-King, Tomiyama, Hiroyuki , Uitti, Ryan J. , Wirdefeldt, Karin , Xiromerisiou, Georgia , Yueh, Kuo-Chu, Zhao, Yi , Gasser, Thomas , Maraganore, Demetrius M. , Krüger, Rejko , Boyle, R.S, Sellbach, A, Siebert, G., Pickut, Barbara , Engelborghs, Sebastiaan , Meeus, Bram, Deyn, Peter Paul De, Cras, Patrick , Agid, Yves, Anheim, Mathieu , Bonnet, A-M, Broussolle, E. , Corvol, Jean‐Christophe , Destée, A., Durif, F., Lesage, Suzanne , Lohmann, Ebba , Pollak, Pierre, Rascol, Olivier , Tison, François , Viallet, François, Amouyel, Philippe , Loriot, Marie‐Anne , Mutez, Eugénie , Duflot, Aurélie , Legendre, Jean-Philippe, Waucquier, Nawal, Schulte, Claudia , Klein, Christine , Djarmati, Ana, Hagenah, Johann, Lohmann, Katja , Hilker, Rüdiger, Loo, Simone van de, Tsimourtou, Vaïa, Ralli, Styliani, Kountra, Persa, Patramani, Gianna, Vogiatzi, Cristina, Hattori, Nobutaka, Yoshino, Hiroyo , Li, Yuanzhe, Imamichi, Yoko, Gibson, J. Mark , Ialongo, Tàmara, Brighina, Laura , Corradi, B., Piolti, Roberto, Tarantino, Patrizia, Kłodowska-Duda, Gabriela, Boczarska‐Jedynak, Magdalena , Tan, Eng King, Olson, Lars, Westerlund, Marie, Sydow, Olof , Puschmann, Andreas , Lin, J-J , J, Eric Ahlskog, Lesnick, Timothy G. , Rocca, Walter A. , Checkoway, Harvey , Westenberger, Ana , Ioannidis, John P. A. , Bertram, Lars , Hadjigeorgiou, Georgios M. , Mok, Vincent , Rogaeva, Ekaterina A. , Stefanis, Leonidas , Toda, Tatsushi , Wszołek, Zbigniew K. , O’Sullivan, John D. , Sutherland, Greg T. , Dissanayaka, Nadeeka N. , Borg, Michael , Damier, Philippe , Dürr, Alexandra , Tranchant, Christine , Vidailhet, Marie , Tzourio, Christophe , Rieß, Olaf , Berg, Daniela , Dardiotis, Efthimios , Funayama, Manabu , Valente, Enza Maria , Ferraris, Alessandro , Dallapiccola, Bruno , Annesi, Ferdinanda , Belin, Andrea Carmine , Olson, Lars, Galter, Dagmar , Nilsson, Christer C. , Andrade, Mariza de , Lang, Anthony E , Ross, Owen A , Puschmann, Andreas , Klein, Christine , Amouyel, Philippe , Corvol, Jean-Christophe , Mutez, Eugénie , Schulte, Claudia , Brice, Alexis

Mayo Clinic

Neurology | July 12, 2012 | Volume: 79 | Issue: 7 | Pages: 659-667

10.1212/wnl.0b013e318264e353 | PMID 22786590 Get It

Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis
Mauguen, Audrey , Péchoux, C. Le , Saunders, Michele I., Schild, Steven E. , Turrisi, Andrew T., Baumann, Michaël , Sause, William T. , Belani, Chandra P. , Bonner, James A. , Zajusz, A. , Dahlberg, Suzanne E. , Nankivell, Matthew , Mandrekar, Sumithra J. , Behrendt, Katarzyna, Koch, Rainer , Bishop, James F., Dische, Stanley, Arriagada, R. , Ruysscher, Dirk De , Pignon, Jean‐Pierre , Ball, David , Paulus, Rebecca , Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | July 3, 2012 | Volume: 30 | Issue: 22 | Pages: 2788-2797

10.1200/jco.2012.41.6677 | PMID 22753901 Get It

Purpose In lung cancer, randomized trials assessing hyperfractionated or accelerated radiotherapy seem to yield conflicting results regarding the effects on overall (OS) or progression-free survival (PFS). The Meta-Analysis of Radiotherapy in Lung Cancer Collaborative Group decided to address the role of modified radiotherapy fractionation. Material and Methods We performed an individual patient data meta-analysis in patients with nonmetastatic lung cancer, which included trials comparing modified radiotherapy with conventional radiotherapy. Results In non–small-cell lung cancer (NSCLC; 10 trials, 2,000 patients), modified fractionation improved OS as compared with conventional schedules (hazard ratio [HR] = 0.88, 95% CI, 0.80 to 0.97; P = .009), resulting in an absolute benefit of 2.5% (8.3% to 10.8%) at 5 years. No evidence of heterogeneity between trials was found. There was no evidence of a benefit on PFS (HR = 0.94; 95% CI, 0.86 to 1.03; P = .19). Modified radiotherapy reduced deaths resulting from lung cancer (HR = 0.89; 95% CI, 0.81 to 0.98; P = .02), and there was a nonsignificant reduction of non–lung cancer deaths (HR = 0.87; 95% CI, 0.66 to 1.15; P = .33). In small-cell lung cancer (SCLC; two trials, 685 patients), similar results were found: OS, HR = 0.87, 95% CI, 0.74 to 1.02, P = .08; PFS, HR = 0.88, 95% CI, 0.75 to 1.03, P = .11. In both NSCLC and SCLC, the use of modified radiotherapy increased the risk of acute esophageal toxicity (odds ratio [OR] = 2.44 in NSCLC and OR = 2.41 in SCLC; P < .001) but did not have an impact on the risk of other acute toxicities. Conclusion Patients with nonmetastatic NSCLC derived a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignificant trend was observed for SCLC. As expected, there was increased acute esophageal toxicity.